PDS Biotechnology Stock

PDS Biotechnology EBIT

The EBIT of PDS Biotechnology (PDSB) as of Aug 10, 2026 is -31.54 M USD. In the previous year, EBIT was -36.32 M USD — a change of -13.15% (higher).

EBIT

-31.54 MUSD

YoY

-13.15%

Last updated:

In 2026, PDS Biotechnology's EBIT was -31.54 M USD, a -13.15% increase from the -36.32 M USD EBIT recorded in the previous year.

The PDS Biotechnology EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M USD)
Date
EBIT (M USD)
Jan 1, 2023
-43.22 base
Jan 1, 2024
-36.32 base
Jan 1, 2025
-31.54 base
Jan 1, 2026 (e)
-37.49 base
Jan 1, 2027 (e)
-42.84 base
Jan 1, 2028 (e)
-55.96 base
Jan 1, 2029 (e)
44.68 base
Jan 1, 2030 (e)
158.27 base
YEAREBIT (M USD)
2030 est 158.27
2029 est 44.68
2028 est -55.96
2027 est -42.84
2026 est -37.49
2025 -31.54
2024 -36.32
2023 -43.22
2022 -41.67
2021 -21.44
2020 -14.90
2019 -15.51
2018 -43.10
2017 -51.97
2016 -39.68
2015 -26.50
2014 -13.19
2013 -6.49
2012 -4.69
Access this data via the Eulerpool API

PDS Biotechnology Revenue

PDS Biotechnology Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
0.00 USD
-43.22 M USD
-42.94 M USD
Jan 1, 2024
0.00 USD
-36.32 M USD
-37.61 M USD
Jan 1, 2025
0.00 USD
-31.54 M USD
-34.50 M USD
Jan 1, 2026 (e)
11.25 M USD
-37.49 M USD
-27.23 M USD
Jan 1, 2027 (e)
23.15 M USD
-42.84 M USD
-26.19 M USD
Jan 1, 2028 (e)
3.80 M USD
-55.96 M USD
-24.09 M USD
Jan 1, 2029 (e)
93.41 M USD
44.68 M USD
26.19 M USD
Jan 1, 2030 (e)
196.92 M USD
158.27 M USD
79.08 M USD

PDS Biotechnology Margins

PDS Biotechnology stock margins

The PDS Biotechnology margin analysis displays the gross margin, EBIT margin, as well as the profit margin of PDS Biotechnology. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for PDS Biotechnology.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
0.00 %
- %
- %
Jan 1, 2024
0.00 %
- %
- %
Jan 1, 2025
0.00 %
- %
- %
Jan 1, 2026 (e)
0.00 %
-333.20 %
-242.07 %
Jan 1, 2027 (e)
0.00 %
-185.05 %
-113.11 %
Jan 1, 2028 (e)
0.00 %
-1,472.51 %
-633.95 %
Jan 1, 2029 (e)
0.00 %
47.83 %
28.03 %
Jan 1, 2030 (e)
0.00 %
80.37 %
40.16 %

PDS Biotechnology Stock analysis

What does PDS Biotechnology do? PDS Biotechnology Corporation is a biopharmaceutical company founded in 2005. It is based in New Jersey, USA and employs around 35 employees. The company specializes in the development of drugs and therapies for the treatment of cancer and infectious diseases. PDS Biotechnology's business model is based on the use of a technology platform called Versamune®. This platform allows for the embedding of immunomodulatory agents in vaccines and cancer therapies. The goal is to activate and strengthen the body's immune defense against cancer and infections. PDS has four different divisions: cancer immunotherapies, infectious diseases, vetmedica, and research services. PDS's cancer immunotherapies focus on stimulating the immune system to help the body recognize and fight cancer cells. The Versamune® technology is used in combination with peptide-based vaccines. Versamune® is intended to help generate a strong and sustained immune response. The most advanced projects in cancer immunotherapy include PD1 vaccines and the PD1 vaccine combination program. PDS is also working on the development of Versamune®-based treatment options in the areas of infectious diseases and vetmedica. Advanced platform technologies have been developed based on the use of Versamune® and choice peptide fusion proteins. In the field of research services, PDS offers a range of services related to its technology platform. These include the manufacturing of Versamune® products, preclinical studies, as well as analysis and consulting. One of PDS's projects, currently being tested in clinical phase IIa, is a vaccine against human papillomavirus (HPV). HPV is a virus that plays a significant role in the development of various types of cancer, such as cervical cancer. The vaccine aims to strengthen the immune system against HPV and thereby reduce the risk of developing cancer. In addition to developing new drugs, PDS has also focused on improving existing treatment options. The company collaborates closely with research institutions and other companies to leverage new insights and technologies in order to develop better therapies. PDS Biotechnology is an emerging company with promising products and a strong commitment to developing groundbreaking therapies for the treatment of cancer and infectious diseases. Through the use of its Versamune® technology and expertise in immunotherapy, the company has the potential to change the future of medicine and improve the lives of millions of people. PDS Biotechnology is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing PDS Biotechnology's EBIT

PDS Biotechnology's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of PDS Biotechnology's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

PDS Biotechnology's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in PDS Biotechnology’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about PDS Biotechnology stock

EBIT of PDS Biotechnology is -31.54 M USD in 2026.

EBIT of PDS Biotechnology changed from -36.32 M USD to -31.54 M USD, representing a -13.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT PDS Biotechnology since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's PDS Biotechnology historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — PDS Biotechnology

All Key Metrics — PDS Biotechnology